NodThera is developing a new class of potent, selective small‑molecule NLRP3 inflammasome inhibitors, with its lead candidate NT‑0167 in a Phase 1 first‑in‑human study assessing safety, tolerability, pharmacokinetics and pharmacodynamics. In preclinical work NT‑0167 showed potent and selective inhibition of NLRP3 with reductions in IL‑1β and IL‑18. The company intends to use recent financing to advance NT‑0167 through clinical studies and to progress additional compounds, including brain‑penetrant NLRP3 inhibitors for central nervous system indications. NodThera also plans continued drug discovery to expand its pipeline of differentiated NLRP3 inhibitors. The company highlights a management team and science focused on exploiting inflammasome biology and chemistry. NodThera maintains offices in Cambridge (UK), Seattle (WA) and Boston (MA). NodThera discovers and develops next-generation small-molecule inhibitors of the NLRP3 inflammasome, a multi-protein complex that initiates innate immune responses. The company’s strategy is to advance its lead drug candidate to proof-of-concept in humans in an inflammatory disease and to progress additional candidates addressing neurodegenerative diseases and certain cancers. NodThera was created and seed-funded by Epidarex Capital in 2016 based on earlier research conducted at Selvita, which remains a shareholder. Alan Watt, PhD MBA, serves as Chief Scientific Officer and acting Chief Executive Officer. In June 2018 the company completed a second closing of a £28m ($40m) Series A financing. The round also prompted board changes, with Henrijette Richter and Scott Rocklage joining the board and Richter set to serve as Chair.

Total raised

$92M

Funding rounds

2

Latest round

Series B

Latest activity

Jun 2020